Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01500551 · ClinicalTrials.gov registry record · Phase 2
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
A Phase 2 study of Juvenile Idiopathic Arthritis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 302
- Enrollment target
- 20
- Study locations
NCT01500551 is a Phase 2 study of Juvenile Idiopathic Arthritis that has completed, run by Pfizer. The registered enrollment target is 302 participants, above the 265-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT01500551, a Phase 2 study of Juvenile Idiopathic Arthritis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 302 participants
- Enrollment target
- 20
- Study locations
Study Summary
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
Conditions Studied
Interventions
- DRUG Tofacitinib
Study Locations (20)
California
- Loma Linda University Children'S Hospital - Loma Linda
- Loma Linda University Clinical Trials Center - Loma Linda
- Loma Linda University Eye Institute - Loma Linda
- Loma Linda University General Pediatric Clinic - Meridian - Loma Linda
- Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology) - Loma Linda
- Children's Hospital Los Angeles - Los Angeles
- Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology) - San Bernardino
- Rady Children's Hospital Center for Pediatric Clinical Research - San Diego
- Rady Children's Hospital Rheumatology Clinic - San Diego
- Rady Children's Hospital San Diego- Education and Office Building - San Diego
- Rady Children's Hospital San Diego - San Diego
- Rady Children's Research Pharmacy - San Diego
Georgia
- Center for Advanced Pediatrics - Atlanta
- AU Medical Center - Augusta
- Augusta University - Augusta
District of Columbia
- Children's National Medical Center - Washington D.C.
- IDS Pharmacy - Washington D.C.
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Connecticut Children's Medical Center - Hartford
Florida
- Nicklaus Children's Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2013-03-18 |
| Est. Completion | 2025-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01500551
The ClinicalTrials.gov registry entry for NCT01500551 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 265-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (14% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Juvenile Idiopathic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Tofacitinib is the first listed.
NCT01500551 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Georgia, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01500551 about?
NCT01500551 is a clinical study titled "Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis". Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
What is the current status of trial NCT01500551?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2013-03-18. Estimated completion is 2025-02-12.
What conditions does trial NCT01500551 study?
This clinical trial studies the following conditions: Juvenile Idiopathic Arthritis.
What interventions are being tested in trial NCT01500551?
The interventions under investigation include: Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT01500551?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01500551 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Idiopathic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
RECRUITING · Phase 3
-
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
RECRUITING
-
Pain in Juvenile Arthritis
RECRUITING · NA
-
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
ACTIVE NOT RECRUITING
-
Juvenile Idiopathic Arthritis (JIA) Registry
COMPLETED
-
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.